Inhibrx Biosciences, Inc.
INBXHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. At a $1.78B market cap, Inhibrx Biosciences, Inc. ranks as a small-cap company within healthcare. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Market Cap
$1.78B
Beta
3.67
P/E (TTM)
—
P/E (Fwd)
-13.83
EPS (TTM)
$-8.81
EPS (Fwd)
$-8.76
ROE
-1773.6%
ROA
-43.6%
Cash
$133.3M
Total Debt
$181.6M
Free CF
-$85.1M
52W Change
320.1%
Annual Financials
Cash vs Debt
Where INBX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INBX finished 36.58% above its 150-day moving average ($91.50) and 41.16% above its 200-day moving average ($88.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INBX overbought or oversold?
At the September 3, 2026 close, INBX's RSI(14) was 74.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Inhibrx Biosciences, Inc. carries $181.6M in total debt against $133.3M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$85.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -1773.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $1.3M (2022) to $1.3M (2025).
A beta of 3.67 means INBX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing INBX.